Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Filings indexed 1,392 across all filing types
Latest filing 2013-07-01 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2013-07-01 English
4 Filing
Director's Dealing
2013-07-01 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about an amended letter agreement, an amendment to a preferred shares rights agreement, and waiver of a Delaware law voting requirement. It does not contain financial statements or detailed financial analysis but rather disclosures about agreements and corporate governance matters. The document also references exhibits and a press release. This type of filing is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into more specific categories like Annual Report, Earnings Release, or M&A Activity. The length and detail confirm it is not a brief announcement but a substantive regulatory disclosure. Confidence is high due to the clear identification as a Form 8-K and the nature of the content.
2013-06-20 English
4 Filing
Director's Dealing
2013-06-13 English
4 Filing
Director's Dealing
2013-06-13 English
4 Filing
Director's Dealing
2013-06-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.